Propanc Biopharma Enters Material Definitive Agreement
Ticker: PPCB · Form: 8-K · Filed: Aug 30, 2024 · CIK: 1517681
| Field | Detail |
|---|---|
| Company | Propanc Biopharma, Inc. (PPCB) |
| Form Type | 8-K |
| Filed Date | Aug 30, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $85,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation
TL;DR
Propanc Biopharma just signed a big deal with a financial obligation. Keep an eye on this.
AI Summary
Propanc Biopharma, Inc. entered into a material definitive agreement on August 26, 2024. This agreement creates a direct financial obligation for the registrant. The filing also includes financial statements and exhibits related to this event.
Why It Matters
This filing indicates Propanc Biopharma has entered into a significant agreement that creates a financial obligation, which could impact its financial standing and future operations.
Risk Assessment
Risk Level: medium — Entering into new material definitive agreements, especially those creating financial obligations, inherently carries risks related to the terms and execution of the agreement.
Key Players & Entities
- Propanc Biopharma, Inc. (company) — Registrant
- August 26, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Propanc Biopharma?
The filing states that Propanc Biopharma, Inc. entered into a material definitive agreement on August 26, 2024, which creates a direct financial obligation for the registrant. Specific details of the agreement are not provided in this summary.
What is the earliest event date reported in this 8-K filing?
The earliest event date reported in this 8-K filing is August 26, 2024.
What is the primary business of Propanc Biopharma, Inc. according to the filing?
According to the filing, Propanc Biopharma, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
Where is Propanc Biopharma, Inc.'s principal executive office located?
Propanc Biopharma, Inc.'s principal executive office is located at 302, 6 Butler Street, Camberwell, VIC, 3124, Australia.
What type of SEC filing is this and what items are being reported?
This is a Form 8-K (Current Report) reporting on the 'Entry into a Material Definitive Agreement', 'Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant', and 'Financial Statements and Exhibits'.
Filing Stats: 500 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-08-30 17:25:53
Key Financial Figures
- $85,000 — ompany an aggregate principal amount of $85,000 AUD. The Company intends to use the net
Filing Documents
- form8-k.htm (8-K) — 36KB
- 0001493152-24-034647.txt ( ) — 201KB
- ppcb-20240826.xsd (EX-101.SCH) — 3KB
- ppcb-20240826_lab.xml (EX-101.LAB) — 33KB
- ppcb-20240826_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 30, 2024 PROPANC BIOPHARMA, INC. By: /s/ James Nathanielsz Name: James Nathanielsz Title: Chief Executive Officer and Chief Financial Officer